This page shows the latest raltegravir news and features for those working in and with pharma, biotech and healthcare.
which is currently led by blockbuster integrase inhibitor Isentress (raltegravir).
Other new drugs backed by the CHMP include Merck &Co's Dutrebis (lamivudine/raltegravir), another addition to the growing list of combination regimens for HIV.
Other integrase inhibitors. Raltegravir ( Isentress; Merck) was the first integrase inhibitor to be approved by the US FDA in October 2007. ... Raltegravir has since been launched in several countries worldwide for use in combination with other
The approval covers the use of this Isentress (raltegravir) formulation in children as young as four weeks of age who weigh at least 3kg.
Tivicay is the third entrant in the integrase inhibitor class after Merck &Co's Isentress (raltegravir) - which was first approved in 2007 - and Gilead Sciences' elvitegravir which was approved last year
a twice-daily treatment with rival integrase inhibitor Isentress (raltegravir) from Merck &Co and found they were equivalent in previously-untreated HIV patients.
More from news
Approximately 1 fully matching, plus 26 partially matching documents found.
We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...